Literature DB >> 18405986

Can protons improve SBRT for lung lesions? Dosimetric considerations.

Dietmar Georg1, Martin Hillbrand, Markus Stock, Karin Dieckmann, Richard Pötter.   

Abstract

BACKGROUND AND
PURPOSE: The aim of the present study was to investigate potential dosimetric benefits of proton therapy for hypofractionated stereotactic body radiotherapy (SBRT). MATERIALS AND
METHOD: Twelve patients undergoing hypofractionated SBRT at the Medical University Vienna were selected. Passively scattered protons (PT) and intensity modulated proton therapy (IMPT) were evaluated against a conformal photon technique (3D-CRT), assuming a fractionation of 3x15Gy, prescribed to the 65% isodose. For all treatment techniques shallow breathing with abdominal compression (SB+AC) was compared with a deep inspiration breath hold technique (DIBH). Treatment planning was done with XiO (CMS, USA). Target conformity, dose-volume histograms (DVH) and various associated dosimetric parameters were considered for the planning target volume (PTV), lung, heart and esophagus.
RESULTS: For both breathing conditions conformity indices were very similar. They were between 0.75 and 0.78 for IMPT and 3D-CRT and around 0.55 for PT using 2-3 beams. Irrespective of treatment modality, DVHs for the ipsilateral lung were improved with the DIBH technique. For the PT technique, the 2Gy isodose (V2Gy) covered on average 7-9% less lung volume compared to 3D-CRT, for IMPT this reduction was more than 10%. Volumes covered the 4 and 6Gy isodoses were 2-4% smaller for IMPT, but very similar for PT and 3D-CRT. Both proton techniques achieved full sparing of the contralateral lung and superior sparing of the heart. Maximum doses to the heart and esophagus were on average around 3Gy for 3D-CRT and almost 0Gy for both proton techniques. For 3D-CRT average V2Gy values for the heart could be reduced from 64% in shallow breathing to 34% in DIBH. V2Gy for protons was negligible.
CONCLUSIONS: Only small dosimetric differences were found between photons and protons for SBRT of lung lesions. Whether these small dosimetric benefits translate in reduced side effects or have the potential to improve local control rates remains to be demonstrated in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405986     DOI: 10.1016/j.radonc.2008.03.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  18 in total

1.  Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer.

Authors:  Arya Amini; Katherine Ciura; James Welsh; Ngoc Nguyen; Matt Palmer; Pamela K Allen; Michael Paolini; Zhongxing Liao; Jaques Bluett; Radhe Mohan; Daniel Gomez; James D Cox; Ritsuko Komaki; Joe Y Chang
Journal:  Med Dosim       Date:  2013       Impact factor: 1.482

2.  On the interplay effects with proton scanning beams in stage III lung cancer.

Authors:  Yupeng Li; Laleh Kardar; Xiaoqiang Li; Heng Li; Wenhua Cao; Joe Y Chang; Li Liao; Ronald X Zhu; Narayan Sahoo; Michael Gillin; Zhongxing Liao; Ritsuko Komaki; James D Cox; Gino Lim; Xiaodong Zhang
Journal:  Med Phys       Date:  2014-02       Impact factor: 4.071

3.  Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.

Authors:  Steven P Register; Xiaodong Zhang; Radhe Mohan; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-07       Impact factor: 7.038

4.  Proton SBRT for medically inoperable stage I NSCLC.

Authors:  Kenneth D Westover; Joao Seco; Judith A Adams; Michael Lanuti; Noah C Choi; Martijn Engelsman; Henning Willers
Journal:  J Thorac Oncol       Date:  2012-06       Impact factor: 15.609

Review 5.  Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.

Authors:  Alexander Chi; Haiquan Chen; Sijin Wen; Haijuan Yan; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2017-05-22       Impact factor: 6.280

6.  Comparisons of dose-volume histograms for proton-beam versus 3-D conformal x-ray therapy in patients with stage I non-small cell lung cancer.

Authors:  Changlu Wang; Hidetsugu Nakayama; Shinji Sugahara; Takeji Sakae; Koichi Tokuuye
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

Review 7.  Proton therapy for non-small cell lung cancer: the road ahead.

Authors:  Eric D Brooks; Matthew S Ning; Vivek Verma; X Ronald Zhu; Joe Y Chang
Journal:  Transl Lung Cancer Res       Date:  2019-09

8.  Lung Stereotactic Body Radiotherapy (SBRT) Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study.

Authors:  Gang Liu; Lewei Zhao; An Qin; Inga Grills; Rohan Deraniyagala; Craig Stevens; Sheng Zhang; Di Yan; Xiaoqiang Li; Xuanfeng Ding
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 9.  Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research.

Authors:  Eugenia Vlaskou Badra; Michael Baumgartl; Silvia Fabiano; Aurélien Jongen; Matthias Guckenberger
Journal:  Transl Lung Cancer Res       Date:  2021-04

10.  Monitoring tumor motion by real time 2D/3D registration during radiotherapy.

Authors:  Christelle Gendrin; Hugo Furtado; Christoph Weber; Christoph Bloch; Michael Figl; Supriyanto Ardjo Pawiro; Helmar Bergmann; Markus Stock; Gabor Fichtinger; Dietmar Georg; Wolfgang Birkfellner
Journal:  Radiother Oncol       Date:  2011-08-30       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.